Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
PaperCitations, authors & open-access status
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 499 citations, 2021 year and closed oa status.
499
Citations
2021
Year
closed
OA Status